ÂÜÀòÂÒÂ×

Dr. Anastasia G. Daifotis, MD is the chief scientific officer of Janssen North America Pharmaceuticals. As leader of the Janssen Scientific Affairs Organization and the Janssen North America Medical and Scientific Affairs Council, she is responsible for shaping the medical and scientific vision for the region and accelerating the development of capabilities essential to winning in a value-based health care system. She leads collaboration with R&D and global partners on developing new therapies and sits on the Global Medical Affairs and Janssen Access Policy Councils.

Dr. Daifotis has extensive pharmaceutical and biotech experience that includes leadership in drug development, medical affairs, and health economics. Dr. Daifotis was formerly with Karos Pharmaceuticals, Inc., a privately-held biopharmaceutical company, where as president and the chief executive officer she led development efforts in pulmonary hypertension and other diseases. Prior to joining Karos, Anastasia was senior vice president of Clinical Development at MacroGenics, Inc., where she oversaw the development of several novel oncologic, infectious disease, and autoimmune therapies. Before joining MacroGenics, Anastasia had a distinguished 16-year career at Merck, where she held R&D, medical affairs, commercial, and leadership roles.

Dr. Daifotis holds a bachelor of arts degree from Princeton University and earned her medical degree from Albany Medical College. She trained in internal medicine at Mount Sinai Medical Center in New York and in endocrinology at the Yale University School of Medicine where she was the recipient of a Howard Hughes Fellowship.